Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

Atypical meningioma is a tumour that arises from the lining of the brain. It mostly affects adults, with most patients in the 40-60 year age group. The primary treatment for atypical meningioma is surgical removal, but with surgery alone up to 40% of patients will experience recurrence. Because of this risk, some clinicians give early radiotherapy, whilst others advise regular monitoring with radiotherapy given only at recurrence. Currently there is no consensus as to which of these two approaches is best. This randomised controlled trial will compare the two approaches, and aims to determine whether early radiotherapy reduces the risk of tumour recurrence compared to regular monitoring in newly diagnosed atypical meningioma.

Primary Sponsor

The Walton Centre NHS Foundation Trust, University of Liverpool, UK

Collaborating Groups

European Organisation for Research and Treatment of Cancer (EORTC) ; Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

15

Closing Date of Accrual

May 2021

Trial Chairperson

Dr Neda Haghighi, Peter MacCallum Cancer Centre, VIC

Trial Contact

ROAM@trog.com.au

Related Post

HeSANDA database for clinical trial data
21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

SMART trial grant
16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed